Related references
Note: Only part of the references are listed.Pancreatic Stereotactic Body Radiation Therapy With or Without Hypofractionated Elective Nodal Irradiation
Jacob A. Miller et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2022)
Ablative 5-Fraction Stereotactic Magnetic Resonance-Guided Radiation Therapy With On-Table Adaptive Replanning and Elective Nodal Irradiation for Inoperable Pancreas Cancer
Michael D. Chuong et al.
PRACTICAL RADIATION ONCOLOGY (2021)
ESTRO ACROP guidelines for target volume definition in pancreatic cancer
Thomas B. Brunner et al.
RADIOTHERAPY AND ONCOLOGY (2021)
Association of Ablative Radiation Therapy With Survival Among Patients With Inoperable Pancreatic Cancer
Marsha Reyngold et al.
JAMA ONCOLOGY (2021)
Preoperative chemoradiotherapy to improve overall survival in pancreatic cancer: Long-term results of the multicenter randomized phase III PREOPANC trial.
Casper H. J. Van Eijck et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Australasian Gastrointestinal Trials Group (AGITG) and Trans-Tasman Radiation Oncology Group (TROG) Guidelines for Pancreatic Stereotactic Body Radiation Therapy (SBRT)
Andrew Oar et al.
PRACTICAL RADIATION ONCOLOGY (2020)
Results of the NRG Oncology/RTOG 0848 Adjuvant Chemotherapy Question-Erlotinib plus Gemcitabine for Resected Cancer of the Pancreatic Head A Phase II Randomized Clinical Trial
Ross A. Abrams et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2020)
Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial
Eva Versteijne et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Patterns of Local Failure After Stereotactic Body Radiation Therapy and Sequential Chemotherapy as Initial Treatment for Pancreatic Cancer: Implications of Target Volume Design
Xiaofei Zhu et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2019)
Radiation Therapy for Pancreatic Cancer: Executive Summary of an ASTRO Clinical Practice Guideline
Manisha Palta et al.
PRACTICAL RADIATION ONCOLOGY (2019)
Elective nodal irradiation with simultaneous integrated boost stereotactic body radiotherapy for pancreatic cancer: Analyses of planning feasibility and geometrically driven DVH prediction model
Akira Nakamura et al.
JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS (2019)
Pattern of Marginal Local Failure in a Phase II Trial of Neoadjuvant Chemotherapy and Stereotactic Body Radiation Therapy for Resectable and Borderline Resectable Pancreas Cancer
Jordan Kharofa et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2019)
Management of Borderline Resectable Pancreatic Cancer
Diego A. S. Toesca et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2018)
Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma A Phase 2 Clinical Trial
Janet E. Murphy et al.
JAMA ONCOLOGY (2018)
Stereotactic Body Radiation Therapy for Locally Advanced Pancreatic Cancer: A Systematic Review and Pooled Analysis of 19 Trials
Fausto Petrelli et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2017)
Alliance for clinical trials in oncology (ALLIANCE) trial A021501: preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas
Matthew H. G. Katz et al.
BMC CANCER (2017)
Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib The LAP07 Randomized Clinical Trial
Pascal Hammel et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer Alliance for Clinical Trials in Oncology Trial A021101
Matthew H. G. Katz et al.
JAMA SURGERY (2016)
Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial
Somnath Mukherjee et al.
LANCET ONCOLOGY (2013)
Radiation Therapy Oncology Group Consensus Panel Guidelines for the Delineation of the Clinical Target Volume in the Postoperative Treatment of Pancreatic Head Cancer
Karyn A. Goodman et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2012)
A Phase I/II Trial of Intensity Modulated Radiation (IMRT) Dose Escalation With Concurrent Fixed-dose Rate Gemcitabine (FDR-G) in Patients With Unresectable Pancreatic Cancer
Edgar Ben-Josef et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2012)
PHASE I STUDY OF PREOPERATIVE SHORT-COURSE CHEMORADIATION WITH PROTON BEAM THERAPY AND CAPECITABINE FOR RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA OF THE HEAD
Theodore S. Hong et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2011)
Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head
Gauri R. Varadhachary et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head
Douglas B. Evans et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Concurrent chemoradiotherapy for advanced pancreatic cancer - 1,000 mg/m(2) gemcitabine can be administered using limited-field radiotherapy
Hideya Yamazaki et al.
STRAHLENTHERAPIE UND ONKOLOGIE (2007)
Definition of elective lymphatic target volume in ductal carcinoma of the pancreatic head based on histopathologic analysis
TB Brunner et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2005)
Share Paper
